Elgemtumab(LJM716)(i.v., 20 mg/kg,once) can reduce pHER3 by 52% and pAKT by 84% in SCID mice with BT474 breast cancer xenografts; while in BxPC-3 pancreatic xenografts In SCID mice, it resulted in a maximum inhibition of pHER3 of 86% and a maximum inhibition of pAKT of 74%[1].
Elgemtumab (LJM716) (20 mg/kg, every other day, 35 days) slows tumor growth in NSG mice with BT474 breast cancer xenografts[1].
